We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current GNFT market cap is 200.59M. The company's latest EPS is EUR -0.5798 and P/E is -6.92.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 40.96M | 7.76M | 85.58M | 26.58M | 38.68M |
| Operating Income | -55.86M | -82.82M | 32.86M | -27.3M | -26.66M |
| Net Income | -65.14M | -101.22M | 67.26M | -23.72M | -28.89M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 309.85M | 198.12M | 281.72M | 215.54M | 173.87M |
| Total Liabilities | 225.79M | 214.55M | 162.62M | 121.01M | 105.92M |
| Total Equity | 84.07M | -16.43M | 119.1M | 94.53M | 67.95M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -47.68M | -96.37M | 99.91M | -72.64M | -55.43M |
| Investing | 327k | -966k | -3.38M | -46.27M | 2.23M |
| Financing | 116.86M | -8.26M | -8.92M | -3.79M | -5.1M |
| Market Cap | 200.59M |
| Price to Earnings Ratio | -6.92 |
| Price to Sales Ratio | 5.17 |
| Price to Cash Ratio | 2.57 |
| Price to Book Ratio | 2.94 |
| Dividend Yield | - |
| Shares Outstanding | 49.83M |
| Average Volume (1 week) | 389.07k |
| Average Volume (1 Month) | 308.93k |
| 52 Week Change | 27.78% |
| 52 Week High | 5.86 |
| 52 Week Low | 2.90 |
| Spread (Intraday) | 0.01 (0.12%) |
| Company Name | Genfit |
| Address |
parc eurasante loos, nord 59120 |
| Website | https://www.genfit.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
